Obermatt
See Similar Stocks →

SIGA Technologies

NMQ:SIGA · US8269171067
PharmaceuticalsSmall

360

63
EV / EBIT31
Price / Owner Earnings13
Owner Earnings Yield86
Dividend Yield100
Price/Sales43
EV / Gross Profit42
Price/Book53
Return on Capital87
Cash Return on Capital91
Return on Equity81
EBIT Margin98
Gross Profitability43
Cash Conversion44
Accruals65
Owner Earnings Margin100
Sales growth15
Profit Growth64
Long-Term EPS Growth10
Owner Earnings Growth23
Reinvestment36
Price momentum26
Debt load90
Refinancing65
Debt Payback100
Liquidity1
Analyst ratings—
Expectations trend50
Market mood26
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

SIGA Technologies clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded1995
Employees40
Websitesiga.com
ISINUS8269171067
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Infectious DiseasesBiotechnology

Description

SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The company sells its lead product, TPOXX (oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets), to the U.S.…

Analysis

Quality compounder

SIGA Technologies, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is fair. The owner-earnings multiple stands at 15.1×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is sturdy. The company scores 10/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
98
2023202420252026

All-time high

98

Mar 2026

All-time low

81

Jan 2023

Average rank

94

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
43
58
63
50
Price/Earnings
3
87
95
91
Price/Book
53
46
35
22
Dividend Yield
100
1
1
1
Value (overall)
83
73
79
57

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare SIGA Technologies with its peers
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Johnson & Johnson
NYQ:JNJ
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Phathom Pharmaceuticals
NSQ:PHAT
37
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
OrganiGram Holdings
TOR:OGI
39
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Veru
NAQ:VERU
23
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Pfizer Limited
NSI:PFIZER
65
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →